Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

[51] These, and newer agents, such as incretin analogs and dipeptidyl peptidase-IV (DPP-IV) inhibitors, have been evaluated for effects on β-cell function and insulin sensitivity. In a second ...

Context: Impairment of incretin activity is now recognized as integral to the metabolic derangement underlying type 2 diabetes. Glucoregulatory agents that target the incretin system have recently ...

Now, with a pipeline chock-full of numerous incretin therapies, the Big Pharma's new strategy will be to test some of those drugs across neurology and immunology indications. "A new focus area ...

The lower sales guidance was a result of sluggish growth in the market for incretin, which increases insulin levels. "Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we expect ...